India Pharma Outlook Team | Friday, 24 October 2025
Takeda Pharmaceutical Company and Innovent Biologics have orchestrated a global strategic alliance worth as much as $11.4 billion to expedite the creation of cutting-edge oncology drugs for solid tumors. The partnership revolves around Innovent’s pioneering immuno-oncology (IO) and antibody-drug conjugate (ADC) programs.
As per the arrangement, Takeda is set to pay $1.2 billion as an upfront consideration, part of which is a $100 million equity investment in Innovent. Besides, Innovent can earn up to $10.2 billion in milestone payments in addition to the tiered royalties on sales to be made in the future. Takeda has acquired global rights (except for the Greater China region) to two late-stage assets — IBI363 and IBI343, along with a license option for the early-stage program IBI3001.
IBI363, a bispecific antibody fusion protein that targets non-small cell lung cancer (NSCLC) and colorectal cancer, will be co-developed globally and co-commercialized in the U.S. where Takeda will be the exclusive rights holder. IBI343 is an ADC aimed at Claudin 18.2 and is currently undergoing late-stage trials for gastric and pancreatic cancers. Takeda is, therefore, taking over the rights for the rest of the world except for China.
Also Read: Torrent Pharma Plans Rs 14,000 Crore Bond Issue Post-Acquisition
Reflecting on the tie-up, Teresa Bitetti, Global Oncology President, Takeda, said it “embodies the cancer therapeutics of the future and consolidates Takeda’s growth potential well beyond 2030.” Dr. Hui Zhou, Innovent’s Chief R&D Officer, was equally upbeat that the agreement perfectly fitted into the company’s vision of providing groundbreaking treatments to under-served patients.”
The agreement positions both companies for continual leadership in the development of radical therapies for complicated solid tumors.
.jpg)
